Spiriva and Renal cell carcinoma - a phase IV clinical study of FDA data

Summary:

Renal cell carcinoma is reported as a side effect among people who take Spiriva (tiotropium bromide monohydrate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Ventolin, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Renal cell carcinoma when taking Spiriva. It is created by eHealthMe based on reports of 155,418 people who have side effects when taking Spiriva from the FDA, and is updated regularly.

What is Spiriva?

Spiriva has active ingredients of tiotropium bromide monohydrate. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 156,666 Spiriva users. Check the latest studies of Spiriva.

What is Renal cell carcinoma?

Renal cell carcinoma (a kidney cancer) is found to be associated with 785 drugs and 1,340 conditions by eHealthMe. Check the latest studies of Renal cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

155,418 people reported to have side effects when taking Spiriva.
Among them, 135 people (0.09%) have Renal cell carcinoma.

Could Spiriva cause Renal cell carcinoma?

Among these 135 people:

How long have people been on Spiriva when they have Renal cell carcinoma? *

Click here to view more results

What is the gender of people who have Renal cell carcinoma when taking Spiriva? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Spiriva and have Renal cell carcinoma?

- Check whether Renal cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Spiriva:

Spiriva (156,666 reports)

Renal cell carcinoma treatments and more:

Renal cell carcinoma (141,599 reports)

How severe was Renal cell carcinoma and when was it recovered:

Renal cell carcinoma in Spiriva

Expand to all the drugs that have ingredients of tiotropium bromide monohydrate:

Renal cell carcinoma and drugs with ingredients of tiotropium bromide monohydrate (138 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Spiriva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Renal cell carcinoma:

Renal cell carcinoma (785 drugs)

Browse all the conditions that are associated with Renal cell carcinoma:

Renal cell carcinoma (1,340 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tiotropium bromide monohydrate (the active ingredients of Spiriva) and Spiriva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.